Close Menu

NEW YORK – The US Food and Drug Administration on Wednesday expanded on a new streamlined pathway to allow developers to quickly obtain a screening claim for COVID-19 tests.

The pathway, which was first announced Tuesday, is expected to enable more widespread use of viral molecular and antigen tests to screen people without symptoms of SARS-CoV-2 infection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.